Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15804318 | 0.95 | GPR119 (0.44) | GPR119OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL6797648 | 0.93 | GPR119 (0.43) | GPR119OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL31283650 | 0.92 | GPR119 (0.43) | GPR119OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL7695449 | 0.86 | GPR119 (0.44) | GPR119OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2334586 | 0.85 | OPRM1 (0.47) | GPR119OPRM1OPRL1GBA1TSHR | |
| SCHEMBL8347586 | 0.85 | TSHR (0.48) | GPR119OPRD1OPRK1GBA1TSHR | |
| SCHEMBL3255190 | 0.85 | GPR119 (0.43) | GPR119OPRD1OPRK1GBA1TSHR | |
| SCHEMBL3786845 | 0.84 | GPR119 (0.43) | GPR119GBA1TSHRALOX15ATM | |
| SCHEMBL8355728 | 0.84 | TSHR (0.45) | GPR119OPRD1OPRK1GBA1TSHR | |
| SCHEMBL5467320 | 0.83 | SMN1; SMN2 (0.55) | OPRM1OPRD1OPRK1OPRL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024261327-A1 | 2-(HETEROARYL-THIO)-1-(HETEROARYL)ETHANONE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024261329-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | Ecstasy LLC (US) | 2023-02-21 | — | — | US | disclosed |
| CN-110662541-B | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2023-02-10 | — | — | CN | disclosed |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2022-12-29 | — | — | US | disclosed |
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | Ecstasy LLC | 2020-06-09 | — | — | US | disclosed |
| CN-110662541-A | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2020-01-07 | — | — | CN | disclosed |
| WO-2018169818-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | WANG XIAODONG (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180258065-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2018-09-13 | — | — | US | disclosed |
| EP-2004625-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | OPRM1, OPRL1, OPRK1 | GPR119 354/4885OPRM1 1/4885OPRD1 4/4885 |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | GPR119 749/4885OPRM1 1304/4885OPRD1 422/4885 |
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | OPRM1, SIGMAR1, OPRK1 | GPR119 385/4885OPRM1 1/4885OPRD1 5/4885 |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | PDE12, NAAA, CYP19A1 | GPR119 802/4885OPRM1 1713/4885OPRD1 539/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | GPR119 1192/4885OPRM1 1717/4885OPRD1 3605/4885 |
| US-20180258065-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRK1 | GPR119 354/4885OPRM1 1/4885OPRD1 4/4885 |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRK1 | GPR119 354/4885OPRM1 1/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.